MeiraGTx Holdings PLC
MGTX
Company Profile
Business description
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Contact
450 East 29th Street
14th Floor
New YorkNY10016
USAT: +1 646 860-7985
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
386
Stocks News & Analysis
stocks
Ask the analyst: Can this genius product create the next ASX software king?
Siteminder’s newly released product for hotel owners and travel agents could widen its moat and see revenue accelerate further.
stocks
Impact of ANZ’s huge fine
Working to prevent repeated failures could also improve competitiveness.
stocks
Acquisition a sign of weakness for overvalued ASX share
Acquisition unlikely to improve prospects in the US and detracts from other opportunities.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,148.80 | 3.70 | -0.04% |
| CAC 40 | 7,896.93 | 71.69 | 0.92% |
| DAX 40 | 23,748.86 | 50.71 | 0.21% |
| Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
| FTSE 100 | 9,277.03 | 6.26 | -0.07% |
| HKSE | 26,486.68 | 40.12 | 0.15% |
| NASDAQ | 22,348.75 | 207.64 | 0.94% |
| Nikkei 225 | 44,931.45 | 163.33 | 0.36% |
| NZX 50 Index | 13,234.89 | 26.58 | 0.20% |
| S&P 500 | 6,615.28 | 30.99 | 0.47% |
| S&P/ASX 200 | 8,875.60 | 5.10 | -0.06% |
| SSE Composite Index | 3,860.78 | 0.28 | 0.01% |